Journal: Brain stimulation
Article Title: Controlling pallidal oscillations in real-time in Parkinson’s disease using evoked interference deep brain stimulation (eiDBS): Proof of concept in the human
doi: 10.1016/j.brs.2022.07.047
Figure Lengend Snippet: (A) Spectrogram (LFP power in the time-frequency domain) of LFP activity during periods in which eiDBS was delivered to suppress and amplify targeted GPi oscillations in a PD patient implanted with a directional DBS lead. (B) Temporal dynamics of modulated oscillations (filtered in the 17–21 Hz range for clear visualization of modulatory effects on ~19 Hz oscillations) in the off-stimulation to suppression, and suppression to amplification transitions. (C) Mean power spectral density (PSD) of LFP activity in the off-stimulation, suppression, and amplification conditions illustrates how eiDBS modulated spontaneous pallidal oscillations across frequencies. (D) Boxplot with independent measurements (mean over 3 s) of the oscillations’ amplitude envelope in the targeted band (16–22 Hz) in the off-stimulation, eiDBS-suppression, and eiDBS-amplification conditions. The box edges represent the interquartile range, and the horizontal line within each box represents the median. Most extreme data points not considered outliers are represented by the whiskers. The amplitude of oscillations significantly decreased from the off-stimulation to the suppression condition (p = 6.12e-08, Cohen’s U3 effect size = 1) and increased from the off-stimulation to the amplification condition (p = 4.04e-8, Cohen’s U3 effect size = 1). P-values were corrected for the two comparisons made using the Bonferroni method. The symbol ✲ indicates that the difference between conditions was statistically significant with the p-values listed above. The number of independent observations (mean amplitude over 3 s) used in this analysis was n = 16 in the off-stimulation, n = 37 in the suppression, and n = 29 in the amplification condition.
Article Snippet: Following intraoperative microelectrode mapping, a directional DBS lead (Boston Scientific Vercise Cartesia model DB-2202-45; 1.5 mm contact height with 0.5 mm vertical spacing) was implanted.
Techniques: Activity Assay, Amplification